0.0115  -0 (-2.54%)		07-26 15:07
Open: 0.011 High: 0.0115 Volume: 561,240		Pre. Close: 0.0118 Low: 0.0096 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.03	1-year :	0.04
Resists	First :	0.02	Second :	0.03
Pivot price	0.01
Supports	First :	0.01	Second :	0.01
MAs	MA(5) :	0.01	MA(20) :	0.01
	MA(100) :	0.03	MA(250) :	0.24
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	7	D(3) :	8.7
RSI	RSI(14): 39.5
52-week	High :	1.57	Low :	0.01

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ EVFM ] has closed above bottom band by 17.7%. Bollinger Bands are 61.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.02 - 0.02	0.02 - 0.02
Low:	0.01 - 0.01	0.01 - 0.01
Close:	0.02 - 0.02	0.02 - 0.02

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Thu, 25 Jul 2024
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st - Quantisnow

Tue, 23 Jul 2024
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1 - StockTitan

Tue, 23 Jul 2024
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1 - PR Newswire

Wed, 17 Jul 2024
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing - Quantisnow

Mon, 15 Jul 2024
Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC - Quantisnow

Wed, 15 May 2024
Evofem Biosciences Announces Financial Results for the First Quarter of 2024 - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: PNK
Sector: Healthcare
Industry: Biotechnology
Shares Out	216 (M)
Shares Float	0 (M)
Held by Insiders	0.1 (%)
Held by Institutions	4.4 (%)
Shares Short	8,680 (K)
Shares Short P.Month	17,820 (K)

EPS	-1.4
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.76
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0.05
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-0.02
PEG Ratio	0
Price to Book value	-0.03
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	2018-01-17
Ex-Dividend Date	Invalid DateTime.